P. Kothare

发表

Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial

J. Northrup, P. Kothare, M. Seger, 2012, BMC clinical pharmacology.

Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing

M. Fineman, B. Cirincione, M. Diamant, 2011, Clinical pharmacokinetics.

Effect of renal impairment on the pharmacokinetics of exenatide

P. Kothare, K. Mace, H. Linnebjerg, 2007, British journal of clinical pharmacology.

Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes

M. Trautmann, P. Kothare, H. Linnebjerg, 2006, Diabetic medicine : a journal of the British Diabetic Association.

Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling

K. Kowalski, K. Bateman, P. Kothare, 2018, Journal of clinical pharmacology.

Harnessing the Potential of Emerging Digital Health and Biological Sampling Technologies for Clinical Drug Development: Promise to Reality

P. Kothare, P. Jadhav, L. Dickmann, 2018, Clinical pharmacology and therapeutics.

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.

R. Kelly, K. Winters, P. Kothare, 2010, Clinical therapeutics.

The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects

K. Winters, P. Kothare, J. Jakubowski, 2010, European Journal of Clinical Pharmacology.

Model-Based Evaluations to Select and Confirm Doses in the Clinical Development of Exenatide

E. Ludwig, A. Baron, M. Fineman, 2007 .

Informing Decisions in Discovery and Early Development Research Through Quantitative and Translational Modeling

S. Visser, C. Gibson, P. Kothare, 2018, Early Drug Development.

Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with Type 2 diabetes.

P. Kothare, M. Seger, M. Mitchell, 2011, International journal of clinical pharmacology and therapeutics.

Leveraging Digital Health Technologies and Outpatient Sampling in Clinical Drug Development: A Phase I Exploratory Study

K. Bateman, P. Kothare, J. Sachs, 2018, Clinical pharmacology and therapeutics.

The Intestinal Uptake of Phenol from Micellar Systems Does Not Conform to the Aqueous Transfer Model

P. Kothare, C. Zimmerman, 2004, Pharmaceutical Research.

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

M. Horowitz, I. Wilding, M. Nauck, 2008, Regulatory Peptides.

Intestinal metabolism: the role of enzyme localization in phenol metabolite kinetics.

P. Kothare, C. Zimmerman, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Effect of Exenatide on the Steady‐State Pharmacokinetics of Digoxin

P. Kothare, K. Mace, H. Linnebjerg, 2005, Journal of clinical pharmacology.

Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.

Prajakti A Kothare, Thomayant Prueksaritanont, X. Chu, 2014, British journal of clinical pharmacology.

Merck's perspective on the implementation of dried blood spot technology in clinical drug development - why, when and how.

Yang Xu, Eric J Woolf, Nancy Gb Agrawal, 2013, Bioanalysis.

Absorption, Metabolism, Distribution, and Excretion of Letermovir.

X. Chu, P. Kothare, J. McCrea, 2021, Current drug metabolism.

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

P. Kothare, M. Mitchell, R. Bergstrom, 2010, BMC psychiatry.

An Integrated Strategy for Implementation of Dried Blood Spots in Clinical Development Programs

K. Bateman, P. Kothare, E. Woolf, 2016, The AAPS Journal.

D2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography: An Open-label Study in Patients with Schizophrenia

S. Kapur, M. Keshavan, M. Laruelle, 2008, Neuropsychopharmacology.

An Integrated Strategy for Implementation of Dried Blood Spots in Clinical Development Programs

K. Bateman, P. Kothare, E. Woolf, 2016, The AAPS Journal.

Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.

M. Fineman, J. Malloy, P. Kothare, 2009, Clinical therapeutics.

Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus

Y. Isaka, M. Fineman, P. Kothare, 2008, Journal of clinical pharmacology.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes.

P. Kothare, K. Mace, H. Linnebjerg, 2009, Endocrine journal.

Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.

P. Kothare, M. Mitchell, K. Jen, 2013, Clinical therapeutics.

Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men

P. Kothare, K. Mace, H. Linnebjerg, 2006, Journal of clinical pharmacology.

Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers

P. Kothare, M. Mitchell, H. Haber, 2013, British journal of clinical pharmacology.

Intestinal metabolism: the role of enzyme localization in phenol metabolite kinetics.

P. Kothare, C. Zimmerman, 2002, Drug metabolism and disposition: the biological fate of chemicals.